Copyright
©The Author(s) 2017.
World J Hepatol. Apr 18, 2017; 9(11): 544-550
Published online Apr 18, 2017. doi: 10.4254/wjh.v9.i11.544
Published online Apr 18, 2017. doi: 10.4254/wjh.v9.i11.544
Table 1 Background of elderly (≥ 75 years old) and non-elderly (< 75 years old) patients
| Parameter | Elderly patients, n = 56 | Non-elderly patients, n = 141 | P |
| Cirrhosis/chronic hepatitis | 30/26 | 44/97 | 0.003 |
| Age in years | 77.8 (75-83) | 65.3 (34-74) | |
| Male/female | 23/33 (41.1%/58.9%) | 54/87 (38.3%/61.7%) | |
| HCV genotype 1b, % | 100 | 100 | |
| HCV RNA, mean log10 IU/mL | 5.85 ± 0.77 | 6.12 ± 0.70 | |
| Pegylated-interferon/ribavirin non-responder, % | 17.9 | 25.5 | 0.251 |
- Citation: Tarao K, Tanaka K, Nozaki A, Sato A, Ishii T, Komatsu H, Ikeda T, Komatsu T, Matsushima S, Oshige K. Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients. World J Hepatol 2017; 9(11): 544-550
- URL: https://www.wjgnet.com/1948-5182/full/v9/i11/544.htm
- DOI: https://dx.doi.org/10.4254/wjh.v9.i11.544